Close Window
Aetna Aetna
Clinical Policy Bulletin:
Ibandronate Sodium (Boniva) Injection
Number: 0727


Aetna considers ibandronate sodium (Boniva) injection medically necessary for the following indications:

  • Treatment of bone metastases or bone pain presumed due to bone metastases from breast cancer
  • Treatment of hypercalcemia of malignancy
  • Treatment of osteoporosis in post-menopausal women who are unable to tolerate either 2 oral bisphosphonates (e.g., alendronate (Fosamax), risedronate (Actonel)) or 1 oral bisphosphonate plus 1 selective estrogen receptor modulator (SERM) (e.g., raloxifene (Evista)), or for whom oral bisphosphonate therapy is contraindicated (e.g., due to inability to swallow, or inability to remain in an upright position after oral bisphosphonate administration for the required length of time)

Aetna considers ibandronate sodium injection experimental and investigational for the following indications (not an all inclusive list) because its effectiveness for these indications has not been established.

  • Giant cell tumor of the spine
  • Inflammatory bowel disease-related osteoporosis
  • Knee osteoarthrosis
  • Multiple myeloma
  • Osteogenesis imperfecta
  • Osteoporosis in men
  • Prevention of postmenopausal osteoporosis
  • Primary biliary cirrhosis-related osteoporosis
  • Solid organ transplantation-related osteoporosis

Note: The World Health Organization (WHO) osteoporosis diagnostic classification assessment (1994) defines osteoporosis as a T score of 2.5 or more standard deviations (SDs) below the mean (i.e., less than -2.5).

See also CPB 0134 - Bone Mass MeasurementsCPB 0524 - Zoledronic AcidCPB 0562 - Biochemical Markers of Bone RemodelingCPB 0666 - Teriparatide (Forteo)CPB 0672 - Pamidronate (Aredia)CPB 0803 - Calcitonin, and CPB 0804 - Denosumab (Prolia and Xgeva).


The National Osteoporosis Foundation Consensus Development Conference (NOF, 2003) defined osteoporosis as a disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk.  Osteoporosis is the most common bone disease in humans.

Peak bone mass in adults is achieved by age 25 to 30 years, and is largely determined by genetic factors; however, nutrition, endocrine status, physical activity, and health during growth also play a contributing role.  Bone loss occurs when bone resorption begins to outpace bone formation.  This imbalance occurs with menopause and advancing age.  After menopause, women experience an accelerated bone loss of 1to 5 % per year for the first 5 to 7 years.  The end result is a decrease in trabecular bone and an increased risk of Colles and vertebral fractures (Hobar, 2005).

Ibandronate sodium (Boniva) (Hoffmann-La Roche Inc., Nutley, NJ) is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption.  It has been developed as a once-monthly oral tablet and as an intravenous (IV) injection.  Both forms have been approved by the U.S. Food and Drug Administration (FDA) in the treatment of postmenopausal osteoporosis. 

The FDA approval of Boniva injection was based on results from the 1-year Dosing Intravenous Administration (DIVA) study, a multinational, randomized, double-blind, active control multi-center study involving approximately 1,300 women with post-menopausal osteoporosis between ages 55 and 80 years.  The study compared the efficacy, safety, and tolerability of once-daily oral ibandronate sodium 2.5 mg regimen with 2 IV ibandronate sodium regimens: 2 mg every 2 months and 3 mg every 3 months, with lumbar spine bone mineral density (BMD) at 1 year as the primary endpoint.  The results showed that the average increase in lumbar spine BMD at 1 year in patients treated with ibandronate sodium injection (3 mg once every 3 months) was statistically superior to that in patients treated with the daily oral tablets (4.5 % versus 3.5 % for the 2 treatments, respectively, p < 0.001).  The study also showed that patients treated with ibandronate sodium injection had consistently higher BMD increases in the total hip and other skeletal sites (femoral neck and trochanter) than patients treated with oral daily ibandronate sodium.

The 2-year findings from the DIVA study were presented at the 2005 Annual Scientific Meeting of the American College of Rheumatology in November 2005.  For patients who received the 3 mg ibandronate sodium injection every 3 months, BMD at the lumbar spine increased more than in the daily oral dosing group (6.3 % versus 4.8 %); substantial increases in bone density at the hip were also observed in the IV group than in the oral daily regimen (3.1 % versus 2.2 %); clinically relevant decreases in bone breakdown (measured by the biochemical marker of bone resorption, serum CTX) were observed in all treatment groups.

The IV regimen was reported to be well-tolerated.  The most common side effects were arthralgia, back pain, influenza/influenza-like symptoms, hypertension, abdominal pain and nasopharyngitis.

The FDA-approved dosing for Boniva injection in the treatment of post-menopausal osteoporosis is 3 mg every 3 months administered IV over a period of 15 to 30 seconds by a health care professional.  It is intended as an alternative for patients who have difficulty with oral bisphophonate dosing requirements, including an inability to sit upright for 30 to 60 mins and/or difficulty in swallowing a pill.  It may also be useful in women who have esophagitis, gastritis, or esophageal or gastric ulcers prohibiting the use of oral bisphosphonates.

Guay (2006) stated that ibandronate is an experimental IV bisphosphonate under study for skeletal complications of bone metastases, as well as hypercalcemia of malignancy.

Intravenous ibandronate has been shown to be effective in treatment of hypercalcemia of malignancy.  Ralston et al (1997) studied the efficacy and safety of intravenous ibandronate in a multicenter study of 147 patients with severe cancer-associated hypercalcemia which had been resistant to treatment with rehydration alone.  Of 131 randomized patients who were eligible for evaluation, 45 were allocated to receive 2 mg ibandronate, 44 patients to receive 4 mg ibandronate, and 42 patients to receive 6 mg ibandronate.  The investigators reported that serum calcium values fell progressively in each group from day 2, reaching a nadir at day 5, and in some patients normocalcemia was maintained for up to 36 days after treatment.  The investigators found the 2-mg dose significantly less effective than the 4-mg or 6-mg dose in correcting hypercalcemia, as the number of patients who achieved serum calcium values below 2.7 mmol/L (10.8 mg/dL) after treatment was 50 % in the 2-mg group compared with 75.6 % in the 4-mg group and 77.4 % in the 6-mg group (p < 0.05; 2 mg versus others).  The investigators reported that ibandronate was generally well-tolerated and no serious drug-related adverse events were observed.  The investigators concluded that ibandronate is a safe, well-tolerated and effective treatment for cancer-associated hypercalcemia.

Pecherstorfer et al (2003) compared the efficacy and safety of ibandronate and pamidronate in patients with hypercalcemia of malignancy.  Seventy-two patients with hypercalcemia of malignancy (serum calcium greater than 2.7 mmol/L) were treated with a single infusion of ibandronate (2 or 4 mg) or pamidronate (15, 30, 60, or 90 mg) on day 0.  The dose was dependent on the severity of hypercalcemia (baseline serum calcium level).  Serum calcium was assessed daily until day 4, then at intervals until day 28.  The primary endpoint was lowering of serum calcium at day 4.  Secondary endpoints included the number of patients responding and time to reincrease following response.  Using the serum calcium baseline approach, the most frequently administered doses were 4 mg ibandronate (78.4 %) and 60 mg pamidronate (50.0 %).  Mean lowering of serum calcium at day 4 was 0.6 mmol/L for ibandronate and 0.41 mmol/L for pamidronate.  The 95 % confidence interval (CI) for the difference ibandronate pamidronate had a lower limit of 0.05 mmol/l, indicating that ibandronate was as effective as pamidronate. The number of patients responding to the 2 agents was also similar; 76.5 % of ibandronate patients and 75.8 % of pamidronate patients were rated as responders after the first dose of study medication.  The median time to reincrease after response was longer for ibandronate (14 days) than pamidronate (4 days) (p = 0.0303).  In the subgroup of 17 patients with high baseline serum calcium (greater than 3.5 mmol/L), ibandronate appeared to be more effective than pamidronate.  The safety profile of both agents was similar.  The investigators concluded that ibandronate is at least as effective as pamidronate in the treatment of hypercalcemia of malignancy.  Furthermore, in patients with higher baseline serum calcium, ibandronate appears to be more effective than pamidronate.  The duration of response is significantly longer with ibandronate than pamidronate.

Pecherstorfer et al (1997) conducted a phase IIb clinical trial to evaluate the hypocalcemic effect and safety of three different doses of ibandronate in hypercalcemia of malignancy. A total of 174 cancer patients with a serum calcium level greater than 2.7 mmol/L (10.8 mg/dL) were enrolled onto the trial.  If hypercalcemia persisted after fluid repletion, patients were randomly assigned to treatment with 0.6 mg, 1.1 mg, and 2.0 mg of ibandronate.  Response, defined as restoration of normocalcemia, was evaluated by an intent-to-treat analysis.  A total of 173 (99 %) patients were assessable for toxicity and 151 (87 %) for efficacy.  The administration of 0.6 mg (group A), 1.1 mg (group B), or 2.0 mg (group C) of ibandronate led to response rates of 44 %, 52 %, and 67 %, respectively.  Significantly more patients in group C responded than in group A (p = 0.0276).  Of the various parameters examined, only the initial serum calcium level (p < .0001; odds ratio, 0.083) and the dose of ibandronate (p = .0162; odds ratio, 2.094) correlated with response.  A total of 195 adverse events were reported, 99 classified as serious and 96 as non-serious; 3 serious and 16 non-serious adverse events were considered related to ibandronate treatment.  The 3 serious adverse events were 1 case with thrombocytopenia, 1 with nausea, and 1 with fever.  The investigators concluded that ibandronate therapy led to a dose-dependent reduction in serum calcium levels.  The response to ibandronate treatment correlated negatively with the initial serum calcium level and positively with the dose administered.  A dose of 2 mg was necessary to achieve a response rate comparable to that in previous studies with pamidronate and clodronate.  The investigators noted that, because the incidence of drug-associated adverse events was low, a dose escalation of ibandronate can be recommended for further clinical trials.

Ibandonate has been found to be effective in treatment of bone metastases in advanced breast cancer.  In a phase III randomized, double-blind, placebo-controlled trial in patients with bone metastases due to breast cancer, 466 women were randomized to receive placebo (n = 158), 2 mg ibandronate (n = 154) or 6 mg ibandronate (n = 154) for up to 96 weeks (Body et al, 2003; Diel et al, 2004).  Treatment was administered intravenously at 3- or 4-weekly intervals.  The primary efficacy parameter was the number of 12-week periods with new bone complications, expressed as the skeletal morbidity period rate (SMPR).  Other clinical endpoints included analgesic use, the incidence of adverse events, quality of life (assessed using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Scale -Core 30 questionnaire (QLQ-C30)), and bone pain (assessed on a 5-point scale from 0 = none to 4 = intolerable).  Ibandronate was generally well-tolerated. S MPR was lower in both ibandronate groups compared with the placebo group; the difference was statistically significant for the ibandronate 6 mg group (p = 0.004 versus placebo).  Consistent with the SMPR, ibandronate 6 mg significantly reduced the number of new bone events (by 38 %) and increased time to first new bone event.  Patients on ibandronate 6 mg also experienced decreased bone pain scores and analgesic use.  Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups, but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28 +/- 1.11, p < 0.001).  A significant improvement in quality of life was demonstrated forpatients treated with ibandronate (p < 0.05) for all global health status.  Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (p = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (p < 0.05).  Significant improvements in the symptoms of fatigue and pain were also observed in the 6-mg ibandronate group.  The investigators concluded that intravenous ibandronate is effective and safe in the palliative treatment of bone metastases from breast cancer.  The investigators found that treatment with ibandronate leads to significant improvements in quality oflife and is well-tolerated.

Ibandonate has been found to be poorly effective in multiple myeloma.  Menssen et al (2002) reported on a double-blind, randomized, placebo-controlled study to assess the efficacy of ibandronate in preventing skeletal-related events (SREs) in advanced-stage multiple myeloma patients.  Patients with multiple myeloma stage II or III were randomly assigned to receive either ibandronate 2 mg or placebo as a monthly intravenous (IV) bolus injection for 12 to 24 months in addition to conventional chemotherapy.  SREs such as peripheral pathologic or vertebral fractures, hypercalcemia, severe bone pain, and bone radiotherapy or surgery were analyzed.  Bone-turnover markers were also studied.  Finally, post hoc analyses of bone morbidity and survival were performed.  A total of 99 patients per treatment group were assessable for efficacy analysis.  The investigators reported that the occurrence of SRE per patient year and the time to first SRE were not significantly different between the 2 treatment groups.  In overall evaluation, no differences were found between the treatment groups regarding bone pain, analgesic drug use, quality of life, and median survival (33.1 versus 28.2 months, respectively).  The investigators concluded that monthly injections of ibandronate 2 mg IV neither reduced bone morbidity nor prolonged survival in the overall population of stage II/III multiple myeloma patients.

Ibandronate has been found to be less effective than pamidronate in multiple myeloma.  Terpos et al (2003) reported on the results of a randomized trial to compare the efficacy of pamidronate and ibandronate in bone turnover and disease activity in multiple myeloma patients.  Patients with stage II or III multiple myeloma were randomly assigned to receive either pamidronate 90 mg (n = 23) or ibandronate 4 mg (n = 21) as a monthly intravenous infusion in addition to conventional chemotherapy.  Skeletal events, such as pathologic fractures, hypercalcaemia, and bone radiotherapy were analyzed.  Bone resorption markers were also studied.  The investigators reported that, in both groups, the combination of chemotherapy with either pamidronate or ibandronate produced a reduction in bone resorption and tumor burden from the second month of treatment, having no effect on bone formation.  However, there was a greater reduction in most markers of bone turnover in the pamidronate group than in the ibandronate group, that being continued throughout the 10-month follow-up of this study.  The investigators reported that there was no difference in skeletal events during this period.  The investigators concluded that a monthly dose of 90 mg of pamidronate was more effective than 4 mg of ibandronate in reducing bone resorption and possibly tumor burden in multiple myeloma.

Guidelines from Cancer Care Ontario have concluded that ibandronate should not be used for treatment of multiple myeloma (Imrie et al, 2004).

Studies of IV ibandronate as an adjunctive treatment for other cancers that tend to metastasize to bone are under way (Guay, 2006).  Whether IV ibandronate will be a therapeutic advance is best answered by randomized, controlled trials.

According to the FDA approved labeling, ibandronate sodium injection is contraindicated in persons with uncorrected hypocalcemia and in persons with known hypersensitivity to ibandronate sodium injection or to any of its excipients.

Kreck and colleagues (2008) stated that osteoporosis is a frequent complication in patients with inflammatory bowel disease.  Recent studies have shown bisphosphonates to considerably reduce fracture risk in patients with osteoporosis, and preventing fractures with bisphosphonates has been reported to be cost effective in older populations.  However, no studies of the cost effectiveness of these agents in preventing fractures in patients with inflammatory bowel disease are available.  These researchers examined the cost effectiveness of ibandronate combined with calcium/colecalciferol ("ibandronate") in patients with osteopenia or osteoporosis due to inflammatory bowel disease.  Treatment strategies used for comparison were sodium fluoride combined with calcium/colecalciferol ("fluoride") and calcium/colecalciferol ("calcium") alone.  A cost-utility analysis was conducted using data from a randomized controlled trial (RCT).  Changes in BMD were adjusted and predicted for a standardized population receiving each respective treatment.  A Markov model was developed, with probabilities of transition to fracture states consisting of BMD-dependent and BMD-independent components.  The BMD-dependent component was assessed using predicted change in BMD from the RCT.  The BMD-independent component captured differences in bone quality and micro-architecture resulting from prevalent fractures or treatment with anti-resorptive drugs. The analysis was conducted for a population with a mean age of the RCT patients (women aged 36 years, men aged 38 years) with osteopenia (T-score about -2.0 at baseline), a population of the same age with osteoporosis (T-score of -3.0 at baseline) and for an older population (both sexes aged 65 years) with osteoporosis (T-score of -3.0).  Outcomes were measured as costs per quality-adjusted life year (QALY) gained from a societal perspective.  The treatment duration in the RCT was 42 months.  A 5-year period was assumed to follow, during which the treatment effects linearly declined to 0.  The simulation time was 10 years.  Prices for medication and treatment were presented as year 2004 values; costs and effects were discounted at 5 %.  To test the robustness of the results, uni-variate and probabilistic sensitivity analyses (Monte Carlo simulation) were conducted.  The "calcium" strategy dominated the "fluoride" strategy.  When the "ibandronate" strategy was compared with the "calcium" strategy, the base-case cost-effectiveness ratios (costs per QALY gained) were between Euro 407,375 for an older female population with osteoporosis and Euro 6,516,345 for a younger female population with osteopenia.  Uni-variate sensitivity analyses resulted in variations between 4 % of base-case results and dominance of calcium.  In Monte Carlo simulations, conducted for the various populations, the probability of an incremental cost-effectiveness ratio of ibandronate below Euro 50,000 per QALY was never greater than 20.2 %.  The authors concluded that the "ibandronate" strategy is unlikely to be considered cost effective by decision makers in men or women with characteristics of those in the target population of the RCT, or in older populations with osteoporosis.

Klause et al (2011) compared the effect of calcium and cholecalciferol alone and along with additional sodium fluoride or ibandronate on BMD and fractures in patients with Crohn's disease (CD).  Patients (n =148) with reduced BMD (T-score < -1) were randomized to receive cholecalciferol (1000 IU) and calcium citrate (800 mg) daily alone(group A, n = 32) or along with additional sodium fluoride (25 mg bid) (group B, n = 62) or additional ibandronate (1 mg IV/3-monthly) (group C, n = 54).  Dual energy X-ray absorptiometry of the lumbar spine (L1 to L4) and proximal right femur and X-rays of the spine were performed at baseline and after 1.0, 2.25 and 3.5 years.  Fracture-assessment included visual reading of X-rays and quantitative morphometry of vertebral bodies (T4 to L4).  A total of 123 (83.1 %) patients completed the 1st year for intention-to-treat (ITT) analysis; 92 (62.2 %) patients completed the 2nd year; and 71 (47.8 %) the 3rd year available for per-protocol (PP) analysis.  With a significant increase in T-score of the lumbar spine by +0.28 ± 0.35 [95 % CI: 0.162 to 0.460, p < 0.01], +0.33 ± 0.49 (95 % CI: 0.109 to 0.558, p < 0.01), +0.43 ± 0.47 (95 % CI: 0.147 to 0.708, p < 0.01) in group A, +0.22 ± 0.33 (95 % CI: 0.125 to 0.321, p < 0.01); +0.47 ± 0.60 (95 % CI: 0.262 to 0.676, p < 0.01), +0.51 ± 0.44 (95 % CI: 0.338 to 0.682, p < 0.01) in group B and +0.22 ± 0.38 (95 % CI: 0.111 to 0.329, p < 0.01), +0.36 ± 0.53 (95 % CI: 0.147 to 0.578, p < 0.01), +0.41 ± 0.48 (95 % CI: 0.238 to 0.576, p < 0.01) in group C, respectively, during the 1.0, 2.25 and 3.5 year periods (PP analysis), no treatment regimen was superior in any in- or between-group analyses.  In the ITT analysis, similar results in all in- and between-group analyses with a significant in-group but non-significant between-group increase in T-score of the lumbar spine by 0.38 ± 0.46 (group A, p < 0.01), 0.37 ± 0.50 (group B, p < 0.01) and 0.35 ± 0.49 (group C, p < 0.01) was observed.  Follow-up in ITT analysis was still 2.65 years.  One vertebral fracture in the sodium fluoride group was detected.  Study medication was safe and well-tolerated.  The authors concluded that additional sodium fluoride or ibandronate had no benefit over calcium and cholecalciferol alone in managing reduced BMD in CD.

Patients with chronic kidney disease have significant abnormalities of bone remodeling and mineral homeostasis and are at increased risk of fracture.  The fracture risk for kidney transplant recipients is 4 times that of the general population and higher than for patients on dialysis.  Ebeling (2007) noted that organ transplant candidates should be evaluated and pre-transplantation bone disease should be treated.  Preventive therapy initiated in the immediate post-transplantation period is indicated in patients with osteopenia or osteoporosis, as further bone loss will occur in the first several months following transplantation.  Long-term organ transplant recipients should also have bone mass measurement and treatment of osteoporosis.  Bisphosphonates are the most promising approach for the management of transplantation osteoporosis.  Active vitamin D metabolites may have additional benefits in reducing hyper-parathyroidism, particularly following kidney transplantation.  The author stated that large, multi-center treatment trials with oral or parenteral bisphosphonates and calcitriol are needed.

In a Cochrane review, Palmer et al (2007) assessed the use of interventions for treating bone disease following kidney transplantation.  Randomized controlled trials and quasi-RCTs comparing different treatments for kidney transplant recipients of any age were selected.  All other transplant recipients, including kidney-pancreas transplant recipients were excluded.  Two authors independently evaluated trial quality and extracted data.  Statistical analyses were performed using the random effects model and the results expressed as relative risk (RR) with 95 % CI for dichotomous variables and mean difference (MD) for continuous outcomes.  A total of 24 trials (n = 1,299) were included.  No individual intervention (bisphosphonates, vitamin D sterol or calcitonin) was associated with a reduction in fracture risk compared with placebo.  Combining results for all active interventions against placebo demonstrated any treatment of bone disease was associated with a reduction in the RR of fracture (RR 0.51, 95 % CI: 0.27 to 0.99).  Bisphosphonates (any route), vitamin D sterol, and calcitonin all had a beneficial effect on the BMD at the lumbar spine.  Bisphosphonates and vitamin D sterol also had a beneficial effect on the BMD at the femoral neck.  Bisphosphonates were more effective in preventing BMD loss when compared head-to-head with vitamin D sterols.  Few or no data were available for combined hormone replacement, testosterone, selective estrogen receptor modulators, fluoride or anabolic steroids.  Other outcomes including all-cause mortality and drug-related toxicity were reported infrequently.  The authors concluded that treatment with bisphosphonates, vitamin D sterol or calcitonin after kidney transplantation may protect against immunosuppression-induced reductions in BMD and prevent fracture.  However, they state that adequately powered clinical studies are needed to ascertain if bisphosphonates are better than vitamin D sterols for fracture prevention in this population.  Moreover, the optimal route, timing, and duration of administration of these interventions remains unknown.

Fahrleitner-Pammer et al (2009) stated that bone loss and fractures are common complications following cardiac transplantation (CTP).  These investigators examined if intravenous ibandronate is an effective preventive option.  A total of 35 male cardiac transplant recipients received either ibandronate (IBN) 2 mg intravenously every 3 months or matching placebo (CTR) in addition to 500 mg calcium carbonate and 400 IE vitamin D(3).  Sera were collected at CTP and every 3 months thereafter.  At baseline and 6 and 12 months, standardized spinal X-rays and BMD measurements were taken.  Bone biopsies were taken at CTP and after 6 months from 6 patients.  In the IBN group, 13 % of the patients sustained a new morphometric vertebral fracture compared with 53 % in the CTR group (absolute risk reduction, 40 %; relative risk reduction, 75 %; p = 0.04).  Bone mineral density remained unchanged with IBN treatment but in the CTR group decreased at the lumbar spine by 25 % and at the femoral neck by 23 % (both p < 0.0001) over the 1-year period.  Serum bone resorption markers carboxy-terminal telopeptide region of type I collagen and tartrate-resistant acid phosphatase 5b were significantly increased in the CTR group and decreased in the IBN group at all time points compared with baseline.  In contrast, both osteocalcin and bone-specific alkaline phosphatase levels showed, after a similar decrease over the first 3 months in both groups, a marked rise in the CTR subjects and steadily declining levels in the IBN patients throughout the remainder of the study period.  Three paired biopsies were available from each group.  Despite the small sample size, a difference in the relative change of eroded surface (68 % in the CTR versus -23 % in the IBN group, p < 0.05) could be shown.  The authors concluded that intravenous IBN reduced fractures, preserved bone mass, and prevented uncoupling of bone formation and resorption after CTP.  This was a small study; its findings need to be validated by further investigation, and comparisons with other alternatives, including oral bisphosphonates.

Spinal giant cell tumors are a rare clinical entity with a high recurrence rate following surgical resection.  Furthermore, complete resection of such lesions remains a challenging surgical problem.  Zhang et al (2011) present 3 complicated cases of giant cell tumor of the spine treated with sodium ibandronate.  One patient with a recurrent giant cell tumor of the 7th thoracic vertebra, 1 patient with a 5th lumbar vertebral giant cell tumor, and 1 patient with recurrent giant cell tumor of the sacrum were treated with sodium ibandronate either post-operatively or upon recurrence of the tumor.  The 1st patient with recurrent thoracic giant cell tumor recovered both clinically and radiologically after treatment with sodium ibandronate without re-operation at 6-years follow-up.  The 2nd patient also recovered with no recurrence of the tumor at 4-years follow-up.  In the 3rd case, although not fully recovered, the recurrent sacral tumor was under control after treatment with sodium ibandronate at 2-years follow-up.  The authors concluded that these case studies demonstrated the potential promise of using sodium ibandronate in the treatment of primary and recurrent giant cell tumors of the spine.  They stated that clinical evaluation should be performed in future studies.

Treeprasertsuk et al (2011) described the effects of parenteral bisphosphonates on BMD changes in primary biliary cirrhosis (PBC) patients with osteoporosis.  A total of 17 PBC patients with osteoporosis diagnosed between 1996 and 2005 were enrolled retrospectively.  All patients received one of the following parenteral bisphosphonates: (i) zoledronic acid, (ii) pamidronate disodium, or (iii) ibandronate sodium.  The median (interquartile-range) age of patients at osteoporosis diagnosis was 62.2 (56.4 to 67.9) and 94 % were women.  After treatment, percent change of lumbar spine-BMD (LS-BMD) and proximal femur-BMD (PF-BMD) of patients with PBC was 2.9% and 0.4%, respectively. Eight patients (47%) showed a greater LS-BMD and/or PF-BMD with percent change of LS-BMD and PF-BMD of 8.7 % and 0.8 %, respectively.  No serious adverse events were found.  In PBC patients with osteoporosis, parenteral bisphosphonates can stabilize BMD for 47 % of patients.  The authors concluded that more prospective studies are needed to evaluate the effectiveness of specific parenteral bisphosphonates in patients with PBC and osteoporosis.

In a Cochrane review, Rudic et al (2012) evaluated the beneficial and harmful effects of bisphosphonates for osteoporosis in PBC.  The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, LILACS,, the WHO International Clinical Trials Registry Platform, and full text searches were conducted until November 2011.  Manufacturers and authors were contacted for additional studies during the conductance of the review.  All RCTs of bisphosphonates in PBC compared with placebo or no intervention, or another bisphosphonate, or any other drug were selected for review.  Two authors extracted data.  RevMan Analysis was used for statistical analysis of dichotomous data with risk ratio (RR) or risk difference (RD) and of continuous data with mean difference (MD) or standardised mean difference (SMD), all with 95 % CI.  Methodological components were used to assess risk of systematic errors (bias).  Trial sequential analysis was also used to control for random errors (play of chance).  A total of 6 trials were included for analysis: 3 trials with 106 participants, of which 2 trials with high-risk of bias, did not demonstrate significant effects of bisphosphonates (etidronate or alendronate) versus placebo or no intervention regarding mortality (RD 0.00; 95 % CI: -0.12 to 0.12, I² = 0 %), fractures (RR 0.87; 95 % CI: 0.29 to 2.66, I² = 0 %), or adverse events (RR 1.00; 95 % CI: 0.49 to 2.04).  Two trials with 62 participants with high-risk of bias compared 1 bisphosphonate (etidronate or alendronate) versus another (alendronate or ibandronate) and found no significant difference regarding mortality (RD -0.03; 95 % CI: -0.14 to 0.07, I² = 0 %), fractures (RR 0.95; 95 % CI: 0.18 to 5.06, I² = 0 %), or adverse events (RR 1.00; 95 % CI: 0.49 to 2.04, I² = 0 %).  Bisphosphonates had no significant effect on liver-related mortality, liver transplantation, or liver-related morbidity compared with placebo or no intervention, or another bisphosphonate.  Bisphosphonates had no significant effect on BMD compared with placebo or no intervention, or another bisphosphonate.  Bisphosphonates compared with placebo or no intervention seem to decrease the urinary amino telopeptides of collagen I (NTx) concentration (MD -16.93 nmol bone collagen equivalents/mmol creatinine; 95 % CI: -23.77 to -10.10; 2 trials with 88 patients; I² = 0 %) and serum osteocalcin (SMD -0.81; 95 % CI: -1.22 to -0.39; 3 trials with 100 patients; I² = 34 %) concentration.  The former result was supported by trial sequential analysis, but not the latter.  Alendronate compared with another bisphosphonate (ibandronate) had no significant effect on serum osteocalcin concentration (MD -3.61 ng/ml, 95 % CI: -9.41 to 2.18; 2 trials with 47 patients; I² = 82 %) in a random-effects meta-analysis, but it significantly decreased serum osteocalcin (MD -4.40 ng/ml, 95 % CI: -6.75 to -2.05; 2 trials with 47 patients; I² = 82 %), the procollagen type I N-terminal propeptide (MD -8.79 ng/ml, 95 % CI: -15.96 to -1.63; 2 trials with 47 patients; I² = 38 %), and NTx concentration (MD -14.07 nmol bone collagen equivalents/mmol creatinine, 95 % CI: -24.23 to -3.90; 2 trials with 46 patients; I² = 0 %) in a fixed-effect model.  The latter 2 results were not supported by trial sequential analyses.  There was no statistically significant difference in the number of patients having bisphosphonates withdrawn due to adverse events compared with placebo or no intervention (RD -0.04; 95 % CI: -0.21 to 0.12; 2 trials with 46 patients; I² = 0 %), or another bisphosphonate (RR 0.56; 95 % CI: 0.14 to 2.17; 2 trials with 62 patients; I² = 0 %).  One trial with 32 participants and with high-risk of bias compared etidronate versus sodium fluoride without finding significant difference regarding mortality, fractures, adverse events, or BMD.  Etidronate compared with sodium fluoride significantly decreased serum osteocalcin, urinary hydroxyproline, and parathyroid hormone concentration.  Th authors concluded that they did not find evidence to support or refute the use of bisphosphonates for patients with primary biliary cirrhosis.  The data seem to indicate a possible positive intervention effect of bisphosphonates on decreasing urinary amino telopeptides of collagen I concentration compared with placebo or no intervention with no risk of random error.  They stated that there is need for more RCTs assessing the effects of bisphosphonates for osteoporosis on patient-relevant outcomes in PBC.

In a pilot study, Alekseeva et al (2013) evaluated the effectiveness and tolerance of ibandronic acid in patients with osteoporosis (OP) concurrent with osteoarthrosis (OA) in the knee joints (KJ).  A total of 20 female outpatients aged 56 to 77 years with post-monopausal OP and primary KJ OA were examined.  All the patients took ibandronic acid in a dose of 150 mg monthly during a year.  During the treatment, the patients showed a significant reduction in the values of all components of the Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) (pain intensity from 51.7 +/- 11.6 to 34.6 +/- 20.7 mm, stiffness from 96.0 +/- 55.6 to 78.5 +/- 46.6 mm, and functional failure from 783.6 +/- 333.2 to 657.8 +/- 360.9 mm according to a visual analog scale), the Oswestry disability index, as well as in the concentration of markers for bone resorption and cartilage degradation.  The need for non-steroidal anti-inflammatory drugs was stated to decrease.  The authors concluded that ibandronic acid therapy resulted in a significant reduction in pain, KJ stiffness, and locomotor functional failure in patients with gonoarthrosis.  These preliminary findings need to be validated by well-designed studies.

CPT Codes / HCPCS Codes / ICD-9 Codes
Other CPT codes related to the CPB:
96360 - 96361
96365 - 96368
HCPCS codes covered if selection criteria are met:
J1740 Injection, ibandronate sodium, 1 mg
ICD-9 codes covered if selection criteria are met:
140.0 - 202.98, 203.10 - 209.36, 209.75, 230.0 - 234.9 Malignant neoplasm [covered for hypercalcemia of malignancy or skeletal complications of bone metastases from breast cancer] [not covered for multiple myeloma or giant cell tumor of the spine]
733.01 Senile osteoporosis [postmenopausal women who are unable to tolerate either two oral bisphosphonates or one oral bisphosphonate and one selective estrogen receptor modulator (SERM), or for whom oral bisphosphonate therapy is contraindicated]
ICD-9 codes not covered for indications listed in the CPB (not all-inclusive):
203.00 - 203.02 Multiple myeloma
238.0 Neoplasm of uncertain behavior of bone and articular cartilage
555.0 - 555.9 Regional enteritis
556.0 - 556.9 Ulcerative colitis
571.6 Biliary cirrhosis [primary]
715.16 Primary localized osteoarthrosis, lower leg
715.26 Secondary localized osteoarthrosis, lower leg
715.36 Localized osteoarthrosis not specified whether primary or secondary, lower leg
715.96 Osteoarthrosis, unspecified whether generalized or localized, involving lower leg Fibula; knee joint; patella; tibia
733.00 Osteoporosis, unspecified
733.02 - 733.09 Idiopathic, disuse and other osteoporosis
733.90 Disorder of bone and cartilage, unspecified [not covered for the prevention of postmenopausal osteoporosis]
756.51 Osteogenesis imperfecta
V42.0 - V42.9 Organ or tissue replaced by transplant
Other ICD-9 codes related to the CPB:
275.42 Hypercalcemia
E933.7 Adverse effects, intravenous bisphosphonates

The above policy is based on the following references:
  1. National Osteoporosis Foundation (NOF). Physician’s guide to prevention and treatment of osteoporosis. Washington, DC: NOF; 2003. Available at: Accessed May 12, 2006.
  2. No authors listed. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646-650.
  3. Hobar C. Osteoporosis. eMedicine Rheumatology Topic 1693. Omaha, NE:; December 16, 2005. Available at: Accessed Jamy 15, 2006.
  4. U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Boniva label and approval history [website]. Rockville, MD: FDA; January 6, 2006. Available at: Accessed May 16, 2006.
  5. Hoffmann-La Roche Inc. Boniva (ibandronate sodium) injection. Prescribing Information. Nutley, NJ; Hoffmann-La Roche; 2006. Available at: Accessed May 16, 2006.
  6. Hoffmann-La Roche Inc. FDA approves first quarterly I.V. injection for postmenopausal osteoporosis in US. Media News. Nutley, NJ; Hoffmann-La Roche; 2006. Available at: Accessed May 16, 2006.
  7. World Health Organization (WHO). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group. WHO Technical Report Series 843. Geneva, Switzerland: WHO; 1994. Available at: Accessed May 16, 2006.
  8. Warr D, Johnston M; Breast Cancer Disease Site Group. Use of bisphosphonates in women with breast cancer. Practice Guideline Report No. 1-11. Toronto, ON: Cancer Care Ontario (CCO); April 2004. Available at: Accessed October 31, 2007.
  9. Imrie K, Stevens A, Makarski J, et al; Hematology Disease Site Group. The role of bisphosphonates in the management of skeletal complications for patients with multiple myeloma. Practice Guideline Report No. 6-4. Toronto, ON: Cancer Care Ontario (CCO); March 2004. Available at: Accessed October 31, 2007.
  10. Pavlakis N, Schmidt RL, Stockler MR. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005;(3):CD003474.
  11. Guay DR. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy. Pharmacotherapy. 2006;26(5):655-673.
  12. Pecherstorfer M, Rivkin S, Body JJ, et al. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: An open-label trial. Clin Drug Investig. 2006;26(6):315-322.
  13. McLachlan SA, Cameron D, Murray R, et al. Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience. Clin Drug Investig. 2006;26(1):43-48.
  14. Body JJ, Diel IJ, Tripathy D, Bergstrom B. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: Phase III trial results. Eur J Cancer Care (Engl). 2006;15(3):299-302.
  15. Diel IJ, Body JJ, Lichinitser MR, et al.; MF 4265 Study Group. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer. 2004;40(11):1704-1712.
  16. Body JJ, Diel IJ, Lichinitser MR, et al.; MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14(9):1399-1405.
  17. Pecherstorfer M, Steinhauer EU, Rizzoli R, et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: A randomized multicentric comparison to pamidronate. Support Care Cancer. 2003;11(8):539-547.
  18. Terpos E, Viniou N, de la Fuente J, et al. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol. 2003;70(1):34-42.
  19. Menssen HD, Sakalova A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol. 2002;20(9):2353-2359.
  20. Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer. 1997;75(2):295-300.
  21. Pecherstorfer M, Herrmann Z, Body JJ, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol. 1996;14(1):268-276.
  22. Kreck S, Klaus J, Leidl R, et al. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: Cost-utility analysis using a Markov model. Pharmacoeconomics. 2008;26(4):311-328.
  23. Ebeling PR. Transplantation osteoporosis. Curr Osteoporos Rep. 2007;5(1):29-37.
  24. Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev. 2007;(3):CD005015.
  25. Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, et al. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: A randomized double-blind, placebo-controlled trial. Bone Miner Res. 2009;24(7):1335-1344.
  26. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: A pooled analysis of individual patient data. Osteoporos Int. 2009;20(2):291-297.
  27. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364(18):1728-1737.
  28. Klaus J, Reinshagen M, Herdt K, et al. Bones and Crohn's: No benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. World J Gastroenterol. 2011;17(3):334-342.
  29. Zhang W, Zhang Y, Li P, et al. Administration of sodium ibandronate in the treatment of complicated giant cell tumor of the spine. Spine (Phila Pa 1976). 2011;36(17):E1166-E1172.
  30. Treeprasertsuk S, Silveira MG, Petz JL, Lindor KD. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther. 2011;18(5):375-381.
  31. Rudic JS, Giljaca V, Krstic MN, et al. Bisphosphonates for osteoporosis in primary biliary cirrhosis. Cochrane Database Syst Rev. 2011;(12):CD009144.
  32. Levis S, Theodore G. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: Update of the 2007 report. J Manag Care Pharm. 2012;18(4 Suppl B):S1-S15.
  33. Alekseeva LI, Zaitseva EM, Sharapova EP, et al. Evaluation of the efficacy and tolerance of ibandronic acid in patients with osteoarthrosis in the knee joints concurrent with osteoporosis: A pilot study. Ter Arkh. 2013;85(5):30-36.

email this page   

Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
Back to top